Endocrine Abstracts

In 1995 the Royal College of Physicians issued guidelines for the use of radioiodine in hyperthyroidism. They recommended administration of enough radioiodine to achieve euthyroidism, with acceptance of a moderate rate of hypothyroidism e.g. 15–20% at 2 years and 1–3% per annum thereafter. Guide activity was 400–550 MBq for standard hyperthyroidism (mainly Graves’ disease), at least 550 MBq for toxic multinodular goitre, and 300–500 MBq in toxic adenom...

Case history: This 33-year old Scottish female presented in February 2017 with a 3-month history of vomiting, erythematous vesicular pruritic rash and three stone weight loss. The rash started 1 day postpartum in January 2015 and migrated from dorsum of feet to both lower legs, upper thigh and torso. A negative biopsy for pemphigus led the team to suspect necrolytic migratory erythema (NME) in November 2016. Her past medical history includes gestational diabetes with her third...

Introduction: Neuroendocrine neoplasms (NENs) represent a diverse group of tumours with varying clinical presentations and outcomes. Despite advancements in treatment, there remains a need to better understand the behaviour of somatostatin receptors (SSTRs) to monitor disease progression and therapeutic efficacy. Our study aims to evaluate the impact of octreotide acetate (OA), Lanreotide acetate (LA) and Pasireotide (P) on LCC-18 cells, investigating potential mechanisms behi...

Aim: To assess whether adults in Scotland currently receiving growth hormone (GH) meet the NICE criteria for starting and continuing GH replacement.Methods: We surveyed all endocrinologists in Scotland and identified the main centres using GH replacement. A cross-sectional case note review was carried out of all patients commenced on GH.Results: About 208 patients (51% women; 24% professionals, 90% Caucasian) were identified, 69 of...

Background: National Institute for Clinical Excellence (NICE) guidelines for the use of Growth Hormone (GH) replacement in adults with GH deficiency (GHD) were published in 2003, and subsequently ratified for use in Scotland.Aim: To identify all adults in Scotland currently receiving GH and to assess whether they meet the NICE criteria for starting and continuing GH replacement.Methods: All endocrinologists in Scotland were surveye...